BSL-3 lab at National Institute of Virology Kerala unit in Alappuzha ready, awaits certification
Officials said the laboratory would be made operational after it receives certification from the Department of Biotechnology under the Union government. Once functional, the facility will enable Nipah virus testing and final confirmation within the State. Currently, samples should be sent to NIV Pune for final confirmation.
'The BSL-3 lab will become operational soon. The trial run commenced three weeks ago and will continue for three months. Once the trial is complete, we will apply for certification from the Department of Biotechnology. After certification, the lab will be able to conduct diagnostic testing and research for various viral diseases, including Nipah. It can also conduct diagnostics, but not research, on Risk Group 4 pathogens,' said an official.
The National Centre for Disease Control (NCDC) classifies laboratories into different categories from BSL 1 to 4 based on a combination of laboratory practices, safety equipment, and facilities. A BSL-3 lab is a high-containment facility intended for the testing and research of highly pathogenic and infectious agents. These labs include specialised safety systems and engineering controls.
The NIV Kerala unit, functioning under the Indian Council of Medical Research (ICMR), was initially established as a BSL-2 facility in February 2008. It operated with limited infrastructure at the Government Medical College Hospital, Alappuzha, until late 2022, when it was relocated to a newly constructed permanent facility in Kuravanthodu. Prime Minister Narendra Modi virtually inaugurated the new facility in Februray 2024.
At present, the unit undertakes research on various locally prevalent viral diseases, focusing on epidemiological, virological, immunological, entomological and socio-behavioural aspects.
Notably, the NIV Kerala unit was among the first four laboratories in India, apart from NIV Pune, the apex institution, to be designated as a State nodal laboratory for COVID-19 testing at the onset of the pandemic.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
40 minutes ago
- Hans India
CM Revanth Reddy Launches Icore Biologics Industry in Genome Valley
In a significant move for the biotechnology sector, Chief Minister Revanth Reddy visited Samirpet's Genome Valley to lay the foundation stone for the Icore Biologics Industry. The event was attended by Ministers Sridhar Babu and Vivek, along with senior officials and various stakeholders. Speaking at the ceremony, CM Reddy highlighted the crucial role that the Genome Valley has played in establishing Telangana as a leader in the biotechnology industry. "The industries in Genome Valley have brought recognition to Telangana. We produce 33 percent of the country's vaccine production from Genome Valley alone. At a time when the world was gripped by fear of Covid-19, we manufactured vaccines here and were able to supply them to countries around the world," he stated. The establishment of Icore Biologics is expected to further strengthen Telangana's position in the global biotech arena and enhance its contributions to vaccine development and production.
Time of India
an hour ago
- Time of India
'Inspired a billion dreams': PM Modi hails Shubhanshu Shukla's 'courage', terms his mission a milestone after splashdown
NEW DELHI: Prime Minister Narendra Modi on Tuesday hailed Shubhanshu Shukla as the astronaut made splashdown early Tuesday at San Diego coast (local time). "I join the nation in welcoming Group Captain Shubhanshu Shukla as he returns to Earth from his historic mission to Space. As India's first astronaut to have visited International Space Station, he has inspired a billion dreams through his dedication, courage and pioneering spirit," said the PM in a post on X. Further expressing hope for future space missions, he added, "It marks another milestone towards our own Human Space Flight Mission - Gaganyaan ." Soon after the splashdown, Union MoS (Independent Charge) for Science and Technology and Space, Jitendra Singh also hailed the achievement, saying, "It is indeed a moment of pride for the world and a moment of glory for India because one of her sons is coming back with a successful voyage." Shukla has returned to Earth safely with Grace — the Dragon capsule the Axiom-4 crew members were travelling in — splashing down in the Pacific Ocean off the coast of San Diego in Southern California. Grace undocked from the International Space Station (ISS) at 4.45pm (IST) on Monday. The spacecraft carried more than 580 tonnes of cargo, including over 60 experiments, during its 22.5-hour journey back to Earth.
The Hindu
an hour ago
- The Hindu
AIC-CCMB planning trials for Chikungunya vaccine with indigenously developed mRNA technology
CSIR-Centre for Cellular and Molecular Biology (CCMB) Atal Incubation Centre (AIC) is planning to go ahead with the next stage larger-scale trials of the indigenously developed mRNA vaccine technology for tackling Chikungunya. 'Chikungunya is a serious, major debilitating disease in India and it does not yet have a vaccine. We have already demonstrated the ability to make use of mRNA technology to develop vaccines with a 'Proof of Concept' (PoC) during the COVID-19 pandemic. Our lab data trials show our Chikungunya vaccine works,' disclosed AIC-CCMB chief executive officer N. Madhusudhana Rao. Results of lab experiments The lab experiments conducted on animals showed that the vaccine candidate can produce antibodies against Chikungunya proteins. The next phase will be to infect the animals and check if the virus load has decreased upon injecting the developed vaccine, he explained. The CEO said the institute had also completed initial trials into a potential mRNA vaccine to prevent tuberculosis (TB). But, to go into the next stage of animal trials and more elaborate testing, adequate funding is required, for which different options are being explored. How vaccines work? Vaccines work by preparing and training the immune system to identify disease-causing microorganisms and eliminate them quickly when the system encounters them. In mRNA technology, the host cell's immune system is trained to evade the real infection by introducing mRNA of an important protein of the microorganism of concern into the host, said Mr. Rao. Interestingly, though AIC had developed the PoC for mRNA technology in less than a year and had announced the same two years ago, it did not elicit much response from either the Indian industry or foreign collaborators. 'There were a few firms which evinced interest in making use of our mRNA technology for vaccine research. But they never came back with concrete proposals. It is an accepted fact that firms spend millions to take licenses from abroad rather than spend a few lakhs on local technology,' said Mr. Rao, a former senior scientist of the CSIR-CCMB. Comirnaty (by Pfizer) or Spikevax (by Moderna) are based on mRNA technology for COVID and found to be extremely effective. The mRNA technology is considered chemically safe with no long-term challenges. The one developed in AIC-CCMB too is based on the existing mRNA vaccine model. It is as safe as the one approved by the US Food & Drug Administration Agency and had undergone a third party quality check, affirmed the CEO. mRNA works much better on viruses and vaccines can be developed for other diseases faster. 'It is unfortunate that there are few takers for our technology, though many are trying the same through different platforms. But we want to go ahead with our trials for the potential Chikungunya and TB vaccine candidates now with different partners,' added Mr. Rao.
